82% in the untreated group and 75% in the chlorambucil group. The action of chlorambucil appeared to be a complex phenomenon associating beneficial effects consisting in slowing down disease progression to stage B or C (P < .OIL and favoring disease remission with harmful HRONIC LYMPHOCYTIC leukemia (CLL) is a C hematologic malignancy known to have a variable course. Some patients die within 1 year after diagnosis, while others survive much longer and are unlikely to die of leukemia.' The variable course of the disease, the difficulty in establishing prognosis, the fear of damaging an already impaired immune system, and the frequent benign and indolent course without any therapy in an important proportion of CLL patients constituted, in the past, major difficulties in designing clinical trials in this disease. Rai et aI2 made a substantial contribution by defining a five-stage clinical classification, which succeeded in selecting a highrisk group (Rai's stages I11 and IV) characterized by the presence of anemia and/or thrombocytopenia. Considering the importance of adapting therapy to the severity of the disease, the French Cooperative Group on CLL proposed, in 1979, a three-stage (A, B, C) prognostic classification obtained through the use of Cox's model on a prospective and a retrospective series.' The prognostic value of this classification was confirmed on other prospective ~e r i e s~.~ and was adopted by an International Workshop on CLL.' It is still unclear as to whether stage A patients, whose median survival is greater than 10 years, should be treated. In 1980, the French Cooperative Group started a randomized clinical trial in which Stage A patients either remained untreated or received daily chlorambucil. Chlorambucil has been the most 0006-4971/90/7507-0007$3.00/0 effects given by a short survival after disease progression to stage B or C in the chlorambucil group and an increased incidence of epithelial cancers (33 v 19) . as well as an excess of epithelial cancer deaths (13 v3). in the chlorambucil group. As these results suggested an overall harmful effect of chlorambucil, we tried to define, within stage A patients, a group of patients with a low probability of disease progression. W e showed that stage A patients with hemoglobin 2 120 g/L and lymphocyte count < 30 x 109/L had a survival that was not significantly different ( P = .46) from that of the age-and sex-matched French population. These patients, accounting for about 50% of all chronic lymphocytic leukemia patients, should not be treated unless disease progression is observed. 0 1990 by The American Society Of Hem8tOlOgy.
common treatment in CLL for 30 years,8 although its beneficial role has never been proved.
PATIENTS AND METHODS
Criteria for eligibility. Diagnosis of CLL was made on the basis of peripheral lymphocytosis (greater than 15 x 109/L or a minimum of 4 x 109/L for at least the 3 previous months), combined with bone marrow lymphocyte infiltration (defined by more than 30% of lymphocytes in aspirates). Bone marrow biopsy was recommended although not requested. Patients who had not been previously treated for CLL and who were classified as stage A (ie, hemoglobin 2 100 g/L, platelet count 2 100 x 109/L and less than three enlarged areas out of the following five: spleen, liver, cervical, axillary, and inguinal lymph nodes, the latter three counting once whether unilateral or bilateral) according to the (A, B, C) staging proposed by Binet et al' were eligible for this trial. Patients classified as stage B were randomized to receive either chlorambucil or the polychemotherapy cyclophosphamide, endoxan, prednisone (COP), and patients classified as stage C were randomized between the two polychemotherapies COP and CHOP (COP plus doxorubicin). Those patients with an associated neoplasia, a positive Coombs test, or a prolymphocytic leukemia were excluded. The protocol was approved by the ethics committee of the Groupe Hospitalier Pitii-SalpttriBre (Paris, France), but no written informed consent was required according to French regulations at the time.
There were 3 1 participating centers and randomization was performed through a centralized blind telephone assignment procedure, according to stage as determined by the participating center concerned. Stage A patients were randomly allocated either to no treatment or to chlorambucil at the daily oral dose of 0.1 mg/kg given indefinitely. The procedure was not blind.
Chlorambucil dose reductions of 50% were made whenever the neutrophil count fell between 1.0 and 1.5 x 109/L or platelet numbers between SO and 100 x 109/L. Chemotherapy was interrupted whenever neutrophils dropped to less than 1 x 109/L or platelets to less than 50 x 109/L. As these counts rose, normal dosage of chemotherapy was resumed. In case disease progression to stage B or C was observed within the first 9 months after randomization, initial treatment was carried on, but after the first 9 months it was changed for a more aggressive one. In the no-treatment group, patients evolving to stage B were administered chlorambucil while Follow-up examinations were scheduled for the ninth month and every 6 months thereafter and consisted of clinical examination, complete blood count, blood sedimentation rate, Coombs test, immunoelectrophoresis, and quantitation of immunoglobulins. Medullary aspiration and medullary biopsy were recommended, especially in patients undergoing clinical and hematologic remission.
Endpoints. The main endpoint was overall survival from the date of randomization. Three other endpoints, status at the ninth month, disease progression to stage B or C, and disease progression to stage C, were analyzed.
Estimation of sample size was based on the method described by George and Desu? with an expected annual accrual of 100 patients (52% in stage A, 34% in stage B, and 14% in stage C based on reference 3, a type I error of a = .05, a type I1 error of j 3 = .IO for a one-sided test, and hypotheses of treatment benefit in stages B and C. It was computed that altogether 850 CLL patients had to be recruited." However, no hypothesis could be formulated in stage A since, in 1979, survival in stage A was found to be the same as that of the general population in the available ~e r i e s .~ Thus, the trial was aimed at both assessing the effect of chlorambucil and studying the natural history of the disease.
Analysis was made on an intention-to-treat basis. Survival analysis was based on the Kaplan-Meier estimate," the logrank test," and Cox's regression model.13 The findings at the reference date of June 1 , 1987 were used. Standard mortality ratio (SMR) technique^'^ were used to compare survival in groups of patients with survival in the general population.
Follow-up examinations.
Estimation ofsample size. ,1980 toMay31, 1985 were recruited in 3 1 hematology departments and were randomized to receive daily chlorambucil (303 patients) or no treatment (309 patients). This third interim analysis was based on the reference date of June 1, 1987 . No information was available for one patient, nine were lost to follow-up, and 112 died. The mean follow-up was 51 months.
Statistical analysis.

RESULTS
FromMay27
The main characteristics of the two treatment groups are presented in Table 1 . While there are slight imbalances (more enlarged axillary lymph nodes, more enlarged areas, and more hepatomegalies in the untreated group; higher lymphocyte count in the chlorambucil group), this table shows no major differences in the distributions of the clinical and biologic parameters in the two groups.
Among the 112 deaths, 62 occurred in the chlorambucil group and 50 in the untreated group (Fig 1 ; P = .21, two-sided logrank test). The 3-year and 5-year survival rates were 90% and 82%, respectively, in the untreated group and 88% and 75% in the chlorambucil group. Moreover, the treatment comparison was adjusted for 13 parameters using Cox's model. Those 13 parameters were selected as either being imbalanced between the two treatment groups ( Table  1) or being individually predictive for overall survival (Table  2 ). They consisted of age, sex, Karnofsky index, general symptoms, enlarged axillary, cervical and inguinal lymph nodes, splenomegaly, hepatomegaly, hemoglobin, lymphocyte and platelet counts, and bone marrow infiltration. As for the unadjusted test, the adjusted treatment comparison for overall survival still showed a longer survival in the untreated group, but again the difference was not significant (P = .09,
two-sided log-likelihood ratio test).
At the ninth month follow-up examination (Table 3) , clinical and hematologic remission (defined by lymphocyte
x 109/L, and neither adenopathy, splenomegaly, or hepatomegaly) was observed for 124 patients (40%) in the chlorambucil group and partial remission (defined by a decrease of at least 50% in the diameter of the enlarged lymph nodes and a decrease of at least 75% in the lymphocyte count compared with the initial examination) was observed for 88 patients (28%) in the chlorambucil group. Five-year survival rates were 89% for patients undergoing clinical and hematologic remission, 76% for patients with partial remission, 82% for patients with stabilization, and 55% for the remaining patients. Disease progression to stage B or C was significantly slowed down in the chlorambucil group (Fig 2, P = .01, two-sided logrank test): 78 patients in the untreated group and 54 in the chlorambucil group evolved to stage B or C before the reference date. This effect was only limited to progression to stage B since, for progression to stage C alone, no difference was observed (Fig 3, P logrank test) and 39 patients evolved to stage C in both groups.
To further investigate those conflicting results concerning the effect of chlorambucil, we looked a t survival after disease progression and a t the causes of death. Although the two treatment groups were no longer comparable and no valid statistical test could be made, Fig 4 suggests a shorter survival in the chlorambucil group (n = 78), as compared with the untreated group (n = 54), after disease progression to either stage B or stage C: the 2-year survival rates after disease progression were, respectively, 84% in the untreated group and 50% in the chlorambucil group.
As for the causes of death (Table 4) , no information was available for 11 patients in the chlorambucil group and nine patients in the untreated group. Among patients with a known cause of death, an excess of epithelial cancers was found in the chlorambucil group: 13 patients died of epithelial cancer in that group as opposed to only 3 in the untreated group, while 23 patients died of CLL and 15 from other causes in that group as opposed to 19 for both causes in the untreated group. This finding was consistent with the increase in epithelial cancer incidence in the chlorambucil
group (33 cases of epithelial cancer v 19 in the untreated
The results obtained indicate that chlorambucil has a beneficial effect in terms of 9-month remission and of preventing disease progression to stage B. However, no benefit was observed in terms of overall survival, and a harmful effect can be evoked since chlorambucil seems to group). 
Disease progression to stage C according to treatment
favor the occurrence of epithelial cancers and increase resistance to further treatment among those patients with disease progression.
Thus, we tried to define a group of stage A patients with a low probability of disease progression, and to whom, therefore, no treatment should be given. Of course, since the analyses presented below were not initially planned, the results must be taken with some caution and should rather be ifiterpreted as hypotheses to be further validated in other studies. By considering only lymphocyte count and hemoglobin, two parameters that are a t the same time individually predictive of disease progression and survival and are easy to measure, we defined two groups of patients: 474 A patients (hemoglobin 2 120 g/L and lymphocyte count .c 30 x lo9/ L) and 138 A N patients (hemoglobin < 120 g/L or lymphocyte count 2 30 x 109/L). The two groups differed markedly in terms of overall survival (Fig 5; P < two sided logrank test): the 5-year survival rates were 83% in A patients and 62% in A" patients. A' patients had a longer survival, not different from that of the age-and sex-matched French population (Fig 6; P = . 
46, two-sided SMR test).
Among A' patients separately, overall survival was larger in the untreated group, although not significantly (Fig 7; P = .08, two-sided logrank test), and an excess of epithelial cancer deaths was observed in the chlorambucil group (10 v 1) . No difference was observed among AN patients (Fig 8; P = .46, two-sided logrank test). As for disease progression, it was, as expected, markedly slower for A' patients (Fig 9; P < two-sided logrank test), and the results on the effect of chlorambucil found separately for A patients and A" patients were consistent with the results for all stage A patients. 
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DISCUSSION
Several methodologic and statistical features of this trial are worth noting. No blinding of treatment allocation was done because it would not have been practical given the indefinite course of treatment in the chlorambucil group, and blinding could not have been maintained given the biologic effects of chlorambucil. Overall survival was the main response criterion since it is the most clinically relevant criterion for chronic diseases. However, we also considered disease remission and disease progression since they could provide some insight as to the effect of treatment.
The power of the treatment comparison for overall survival was high: for a two-sided test and for a = .05, the power was 95% to detect an increase in 1-year survival from 92% (observed 1-year survival in the chlorambucil group) to 96%, or a decrease from 92% to 84%.9 The crude benefit of no treatment could be estimated as a 6.7% increase in 5-year overall survival (with a 95% confidence interval ranging from -1.5% to 14.9%). Moreover, after using Cox's model to adjust for the 13 parameters given in the Results section, the mortality rate was estimated to be 1.38 times higher in the chlorambucil group (with a 95% confidence interval ranging from 0.85 to 1.91).
Treatment comparison was adjusted on prognostic factors to remove imbalances in favor of the chlorambucil group and to correct the bias in estimating the treatment effect caused by omitting a balanced prognostic factor when considering a censored criterion such as s~rvival.'~ It should be kept in mind that the results presented are those of the third interim analysis and that a more conservative type I error should be used: since five interim analyses were planned, a nominal level of a' = .016 should be used to maintain an overall type I error of a = .05.16 The results obtained are consistent with the results of the first two interim analyses of the CLL 80 protocol which, however, were essentially centered on stage C Finally, we warned against the difficulty in performing analyses separately for A' and AN patients. However, the need to distinguish two groups of patients among stage A patients had been underlined before'," and the fact that A' patients' survival was not different from that of an age-and sex-matched population clearly raises the issue of whether one should treat those patients a t all. Chlorambucil, an aromatic derivative of nitrogen mustards taken orally, was first introduced for the treatment of CLL in 1952 and since has been the most common treatment used in CLL.8.1s The standard daily dose has been 0.1 mg/kg, sometimes 0.2 mg/kg. Also, intermittent schedules using pulse doses of 0.4 to 0.6 mg/kg have been commonly emp l~y e d . '~-~~ Sawitsky et alZ0 found an increased response rate and an improved survival with intermittent chlorambucil plus prednisone as compared with continuous chlorambucil plus prednisone, but neither of these two comparisons achieved statistical significance. The International Society for Chemo and Immunotherapy (IGCI, Vienna, Austria) group2' reported a significantly increased response rate and a significantly improved survival with daily high-dose chlorambucil as compared with intermittent chlorambucil plus prednisone. Whatever the schedule, a response rate of 60%, with 10% to 20% of complete remission, has been reported in several trials, but these results failed to be conclusive given the absence of well-defined criteria for patients' inclusion and the small sample sizes. There has not been any randomized trial including homogeneous groups of patients indicating a beneficial role of chlorambucil in CLL in terms of survival. The only well-accepted notion arising from past trials was the pejorative outcome associated to the absence of therapeutic response as well as the favorable outcome associated with therapeutic response20.23-25 that we confirmed in the present trial.
Our results do not show a beneficial effect and suggest, although do not prove, a harmful effect of chlorambucil when given in a daily regimen to stage A patients. Indeed, the action of chlorambucil appears to be a complex phenomenon combining beneficial and harmful effects. It is clear that chlorambucil is able to prevent disease progression to stage B but it does not appear to affect progression to stage C. Also, response to chlorambucil is correlated with a prolonged survival, suggesting a beneficial role; conversely, patients exhibiting disease progression under chlorambucil therapy have a very short survival. Most patients with disease progression under chlorambucil have an important increase in their tumoral mass (data not shown), suggesting that the drug is probably selecting a resistant clone, which will in most cases also resist further chemotherapeutic agents.
An important and new information emerging from this trial is the higher frequency of epithelial neoplasias in the chlorambucil group, whereas incidence of Richter's syndrome was not increased (9 in the chlorambucil group v 6 in the untreated group). Moreover, no acute leukemia was observed in either group. Previous studies in polycythemia vera26 and rheumatoid arthritisz7 indicated a high incidence of hematologic neoplasias after chlorambucil therapy, but not of epithelial neoplasias. Because intermittent chlorambucil was used in most recent studies and no increase in the incidence of epithelial neoplasia was reported, a possible relationship between the continuous schedule we used and the increase in the incidence of epithelial neoplasia cannot be ruled out. Rai's stage 111) with a 78% 5-year survival rate, while Rai's stage 0 comprises 31% of CLL patients with an 82% 5-year survival rate.6.7 Given the importance of adapting therapy to the severity of the disease and the potential harmful effect of the chemotherapeutic agents for these initial forms of CLL, we attempted to define, within stage A patients, a group of patients with a low potential for disease progression. We feel that the distinction we propose between A' and A" patients can serve as a useful guide in deciding whether stage A patients should be treated or not. However, parameters other than hemoglobin and lymphocyte count could be used as well as other cut-off points. Moreover, it should be noted that A' patients and Rai's stage 0 patients are different since 14% of Rai's stage 0 patients are classified as A" as well as 24% and 39% of Rai's stage I and stage I1 patients, respectively.
In 1984, Han et aI2* reported 20 cases of Rai's stage 0 CLL who did not progress during periods ranging from 6.5 to 20 years. This so-called "benign monoclonal B-cell lymphocytosis" was mainly occurring among females with low lymphocyte count, normal karyotype, preserved immunity, and preferential K phenotype, although initial clinical and hematologic data were found to be unpredictive, as far as evolution was concerned. In 1956, H~u g i e~~ and, in 1966, Galton3' stressed that rapid lymphocyte doubling time was associated with poor prognosis. These initial observations have now been confirmed by many other
In our series, if we segregate stage A patients within the untreated group according to lymphocyte doubling time (<I year for 41 patients, or r l year for 268 patients), it clearly appears that patients with a doubling time lower than 1 year have a poor prognosis, with a 5-year survival rate of 51%, as compared with 86% for patients with a doubling time greater than 1 year (P < two-sided logrank test). Also, a diffuse pattern of bone marrow involvement was found to be correlated with disease progression in stage A patients in two ~t u d i e s .~~. '~ In our series, although a diffuse bone marrow pattern (18% of stage A patients) was not correlated to survival (P = .07, two-sided logrank test), it was correlated to disease progression (P < two-sided logrank test). Taking into account all these criteria, Montserat et all7 recently defined "smouldering" CLL as those stage A patients with hemoglobin t 130 g/L, lymphocyte count t30 x 109/L, nondiffuse bone marrow histologic pattern, and lymphocyte doubling time greater than 12 months.
According to this definition, 172 of our 247 untreated A patients had a smouldering CLL while none of our 62
For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From untreated A" patients did. The advantage of our proposal consists in its simplicity, since it only requires physical examination and hemogram data, and in the fact that it can be used at the initial consultation without needing to wait for 1 year to assess lymphocyte doubling time. Whether the addition of new biologic parameters, such as karyotype and immunologic markers, will be able to provide new and important prognostic information is still an open i s s~e .~~-~*
In conclusion, this randomized clinical trial in stage A patients failed to show any benefit from chlorambucil at a daily indefinite regimen when compared with no treatment. Contrarily, a potential harmful effect of chlorambucil could be evoked. This trial also allowed us to define, within stage A patients, a group of patients comprising 77% of all stage A patients and about 50% of all CLL patients, with a survival not different from a French age-and sex-matched population. These patients should not be treated unless progression is observed.
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